Personal CFO Solutions LLC Buys 1,516 Shares of Zoetis Inc. (NYSE:ZTS)

Personal CFO Solutions LLC grew its stake in Zoetis Inc. (NYSE:ZTS) by 21.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,552 shares of the company’s stock after purchasing an additional 1,516 shares during the quarter. Personal CFO Solutions LLC’s holdings in Zoetis were worth $1,393,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ZTS. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services bought a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Finally, Dunhill Financial LLC increased its position in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $170.34 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The business has a fifty day simple moving average of $166.72 and a two-hundred day simple moving average of $176.78. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The company has a market capitalization of $76.28 billion, a P/E ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is currently 36.56%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Leerink Partners assumed coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.